Cybin Inc. will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The late-stage breakthrough neuropsychiatry company continues developing its pipeline of investigational compounds targeting mental health conditions, with significant progress in multiple clinical trials. The company is currently advancing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development timeline and bringing new treatment options to patients faster.
Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in a Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, targeting various mental health conditions where current treatment options remain limited. Investors and interested parties can access the full press release at https://ibn.fm/BqH38 for complete details about the upcoming conference call. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.
The upcoming financial results presentation and business update will provide stakeholders with important insights into Cybin's progress in developing potential breakthrough treatments for major depressive disorder and generalized anxiety disorder, conditions that affect millions of people worldwide and represent significant market opportunities for innovative pharmaceutical approaches. The company emphasizes its commitment to addressing the large unmet need for people suffering from mental health conditions by developing novel drugs that provide effective and durable results for patients. This update comes at a critical time as the company advances multiple compounds through later-stage clinical development, potentially bringing new treatment paradigms to the neuropsychiatry field.
